Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...

A 66-year-old man whose kidneys were failing is now the fourth person who has received a gene-edited pig kidney, ...

Indian drugmaker Maithili Life Sciences has received a non-compliant report from the Brussels-based Federal Agency for ...

The life science investment firm Bioluminescence Ventures will close its doors less than two years after its founding, ...

The Mitsubishi Chemical Group is selling its centuries-old pharmaceutical business to Bain Capital in a carve-out worth about ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans for regulatory filing this year.

Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsized Nasdaq debut on Friday, and metabolic disease biotech Aardvark Therapeutics outlined plans for a potential $89 ...

Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing ...

Acelyrin merges with Alumis in all-stock deal, transferring $448M cash and lonigutamab asset. Martin Babler to lead combined ...

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

Progyny acquires BenefitBump and Teladoc buys Catapult Health for $65M, as digital health companies engage in dealmaking.

AstraZeneca cuts UK investment after government reduces site expansion support; Viking secures API supply; Jabil acquires ...